Abstract | Multiple clinical trials have demonstrated that intravesical Bacillus Calmette-Guérin (BCG) treatment reduces recurrences and progression in patients with non-muscle-invasive bladder cancer (NMIBC). However, although BCG has been in use for almost 40 years, this agent is often underutilized and practice patterns of administration vary. This neglect is most likely caused by uncertainties about the optimal use of BCG, including unawareness of optimal treatment schedules and about patient populations that most benefit from BCG treatment. To address this deficit, a focus group of specialized urologic oncologists (urologists, medical oncologists and radiation oncologists) reviewed the current guidelines and clinical evidence, discussed their experiences and formed a consensus regarding the optimal use of BCG in the management of patients with NIMBC. The experts concluded that continuing therapy with 3-week BCG maintenance is superior to induction treatment only and is the single most important factor in improving outcomes in patients with NMIBC. They also concluded that a reliable alternative to radical cystectomy in truly BCG-refractory disease remains the subject of clinical trials. In addition, definitions for common terms of BCG failure, such as BCG-refractory and BCG-intolerant, have been formulated.
Introduction
Over the past decade, interest in the use of immuno therapy for cancer treatment has been steadily growing. Early results from clinical trials investigating immuno modulation with the programmed death ligand 1 (PDL1) have contributed to this enthusiasm, particu larly in the field of bladder cancer research. Experts will recognize, however, that immunotherapy for bladder cancer has been successfully used for almost 40 years. BCG was first introduced into clinical use in urology in 1976 and remains the most effective form of intravesi cal treatment for nonmuscleinvasive bladder cancer (NMIBC). Despite this successful history, BCG therapy is internationally underutilized and practice patterns of BCG administration vary widely, probably because of misconceptions about its optimal use. 1 This Expert Consensus Document provides a comprehensive review of immunomodulatory therapy with BCG, clarifies topics that can create confusion and recommends best practice guidelines to improve overall use and patient outcomes (Box 1).
Methods
Contributing authors were invited by the Leo & Anne Albert Institute for Bladder Cancer Care and Research to partake in a symposium designed to evaluate and comment on current practices in bladder cancer. Participants were selected based on their expertise and knowledge in the area of interest. Global literature searches were performed for each section and presen tations made with subsequent group discussion and c onsensus development based on the strength of the data.
Historical perspective
BCG is a live, attenuated form of the slowgrowing, aerobic bovine tuberculosis bacterium, Mycobacterium bovis. In 1900, Albert Léon Charles Calmette and Camille Guérin of the Pasteur Institute in Lille, France, began work on a vaccine against Mycobacterium tuberculosis, one of the species that can cause tuberculosis in humans. They discovered that M. bovis is less virulent after being subcultured in a bilecontaining medium. Now Middlebrook 7H9 medium is usually used. From 1908 to 1913 repeated subculturing of M. bovis resulted in a nonvirulent strain and vaccine trials in humans began in 1921. Before lyophilized storage in 1960, BCG was passaged continually (over 1,000 times), which led to the formation of multiple daughter strains-each strain a genetic variant of the original. Many of these mutants are used today, leading to different possible product characteristics and strengths, as well as varying dosing requirements. Remarkably, as demonstrated by the high complete response rates observed with BCG preparations containing sufficient numbers of live bacteria, all strains are effective and clearly superior to standard intravesical chemotherapy. Although con trolled clinical trials might confirm the superiority of one preparation over another, current shortages of BCG require that we assure both patients and government agencies that current experience suggests that all current BCG preparations are highly effective and superior to nonBCG alternatives.
The first report of BCG as an immunomodulator in cancer therapy was published in 1959. 2 In 1976, Morales and colleagues 3 published a landmark paper on the favourable effect of intravesical BCG on outcomes in recurrent superficial bladder cancer in nine patients. The first controlled trial showing similar results was published in 1980 and BCG received FDA approval for the treatment of superficial bladder cancer in 1990. 4 
Review of current guidelines on BCG use
Several guidelines exist regarding the use of BCG in NMIBC, such as those by the American Urological Association (AUA), 5 the European Association of Urology (EAU), 6 the National Comprehensive Cancer Network (NCCN), 7 the International Bladder Cancer Group (IBCG) 8 and the International Consultation on Urological Diseases (ICUD). 9 Even though each of these guidelines is based on largescale literature reviews on similar avail able data, the guidelines are somewhat disparate, making implementation of the recommendations into routine practice difficult for the practicing urologist.
Low-grade tumours
Consensus exists for small, solitary, superficial lowgrade tumours (Ta) with all groups agreeing that BCG is not indicated in this setting given the very low risk of disease progression. For multiple and/or large or recurrent lowgrade tumours (the intermediaterisk category), BCG therapy with or without maintenance is considered optional by EAU and AUA guidelines and the IBCG. 5, 6, 8 The AUA's metaanalysis suggests 24% and 31% reduc tion in recurrence rates for BCG induction and mainten ance, respectively. 5 The EAU recommendation is based predominantly on the recent metaanalysis by Sylvester and colleagues, 10 which demonstrated a 32% relative risk reduction with the use of BCG maintenance compared with intravesical chemotherapy. The IBCG recommen dation is based on a risk assessment model. 11 By contrast, the NCCN guidelines do not specifically address these intermediaterisk tumours. 7 
High-grade tumours (including carcinoma in situ)
The recommendations for use of BCG in highgrade tumours are relatively consistent across guidelines; variations mainly exist in the recommended duration of therapy. The AUA, EUA and IBCG advise BCG induc tion with 1-3 years of maintenance for all highgrade tumours. 5, 6, 8 ICUD guidelines for Ta highgrade tumours do not include maintenance BCG, remarking a lack of conclusive evidence about the effect of maintenance BCG on disease progression in these tumours. In addi tion, the value of maintenance therapy in T1 disease is questioned. 9 Carcinoma in situ (CIS) is the only patho logy for which maintenance is advised by ICUD and the guideline also includes reinduction of BCG instillations if no response is detected at first evaluation. 9 The NCCN recommends BCG as standard treatment for CIS only, but lists BCG as the favoured option for highgrade Ta and T1 tumours and offers that maintenance should be considered. 7 
Optimal schedule and duration of therapy
The 6week course of intravesical and percutaneous BCG, which was the first reported schedule, 3 is very effective. Most subsequent studies have failed to dem onstrate that alternative schedules provide significant benefits. Early modifications, such as omission of per cutaneous vaccination, and quarterly or monthly main tenance, though accepted, only marginally improve convenience or efficacy. Although randomized clinical trials (RCTs) failed to demonstrate improved efficacy of percutaneous BCG against bladder cancer, systemic immune responses are higher after percutaneous vac cination than after intravesical administration alone. This heightened response after immunization is prom ising and should prompt new RCTs to investigate this a pplication method.
RCTs of quarterly, monthly and repeated 6week BCG instillations, which aim to maintain the immune response, also failed to show a significant improvement of efficacy (Figure 1 ). These results led some experts to question the value of maintenance BCG and to abandon its use. By contrast, the 3week BCG regimen, designed by the Southwest Oncology Group with immunologi cal principles in mind, 12 is sufficiently different that it should not be considered in the same category as other m aintenance BCG regimens. The potential benefit of 3week BCG maintenance deserves emphasis. Specifically, the schedule is initiated with weekly intravesical and percutaneous BCG treat ment for 6 weeks, followed by further weekly combina tion treatment for 3 weeks after routine cystoscopy at 3, 6, 12, 18, 24, 30 and 36 months. 12 Only 14% of patients completed treatment in the original study, but compli ance in modern studies is high. In the population with CIS, complete response at 6 months in patients random ized to receive the initial 6week BCG treatment only (induction arm) was 69% in comparison with 84% (P <0.01) in patients randomized to receive the addi tional 3week maintenance treatment (maintenance arm). 12 In the maintenance arm, complete response increased from 55% at 3 months to 84% at 6 months (64% complete response in patients with treatment failure at 3 months). Even without additional BCG, 26% of patients with residual disease at 3 months in the induction arm went on to have complete response by 6 months, illustrating that 6 months is a preferred time to evaluate response.
Significant improvement in the treatment of CIS was confirmed by other RCTs with 3week maintenance BCG, but no other treatment has level one evidence of superiority over induction BCG. The most commonly used treatment, repeated 6week instillations, has been found to be ineffective in one RCT. 13 Five RCTs com pared non3week maintenance schedules to BCG induction only (Table 1) . [14] [15] [16] [17] [18] None of these alternative maintenance schedules showed a statistically significant reduction in recurrence (range -4% to 22%, average 7%). By contrast, two studies that compared 3week mainten ance to induction treatment alone showed a statistically significant 28% reduction in tumour recur rence (Table 2) . 12, 19 Moreover, only the 3week BCG maintenance schedule reduced disease progression and metasta sis, as well as overall and cancerspecific m ortality in RCTs. 10, 12 Two other trials compared 3week maintenance BCG with alternative agents (Table 2) . 10, 20 EORTC 30911 compared the 3week maintenance BCG with 3week maintenance epirubicin chemotherapy. BCG signifi cantly reduced recurrence by 15%, metastasis by 45% (P = 0.046), and both overall (P = 0.023) and cancer specific mortality (P = 0.026). 10 No other intravesi cal treatment, BCG induction only, or non3week m aintenance BCG schedule has achieved such success.
The lifesaving benefit of BCG immunotherapy in RCTs is confirmed in realworld practice pattern research. In a review of data from nearly 24,000 patients with bladder cancer from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, use of BCG significantly reduced mortality (HR 0.87), and bladder cancer deaths were reduced by 23% in patients with highgrade tumours. 21 Education might now be the most important next step in improv ing care in bladder cancer. The review found that only 22% of eligible patients received BCG, and only a frac tion of those received the critically important 3week maintenance schedule. 
Practical issues of BCG administration
Some practical points need to be considered when using BCG for bladder cancer treatment. BCG manu facturers recommend evaluating the tuberculosis status of the patient with a PPD (purified protein derivative) tubercu losis skin test before initiation of therapy, with some practitioners obtaining chest radiographs in all patients. 22 This procedure has never proven necessary, probably owing to the exceedingly low incidence of tuberculosis in developed nations, where most bladder cancer patients do not meet the criteria for disease screening as recommended by the Centers of Disease Control and Prevention. 23 In fact, patients with a positive PPD test without active disease should not be excluded from BCG therapy, as the presence of a systemic immune response might help augment the antitumour response as noted above. 24 In addition, patients with a positive PPD result were shown to display adverse effect profiles during BCG treatment that are similar to patients with a n egative test. 25 In general, BCG use in patients with significant immuno suppression should be avoided, owing to the infectious risk of BCG. However, other patients with mild immune impairment (for example, due to steroid use for chronic obstructive pulmonary disease), well controlled HIV, or mature transplants, as well as healthy elderly patients, can be treated successfully with minimal adverse effects and good efficacy. 26, 27 In addition, medi cations such as statins or antiplatelet agents are not a contra indication for BCG therapy. Although these drugs have a potential negative effect on the immune response to BCG treatment, neither had an effect on the clinical efficacy of BCG therapy in multiple clinical studies. [27] [28] [29] [30] [31] [32] Other relative contraindications are prosthetic valves or orthopaedic hardware. However, a large phase II study with BCG combination therapy reported no infectious complications in the absence of prophylactic anti biotics, suggesting this population represents a lowrisk setting. 33 This recommendation is in concordance with the American Heart Association's guideline against anti biotic prophylaxis for genitourinary procedures such as u rethral catheterization utilized in BCG administration. 34 The technique used for the administration of BCG therapy must optimize the contact duration of the mycobacterium to the bladder urothelium to achieve maximum treatment effect. These measures include minimizing fluid intake by the patient before treatment and assuring complete bladder drainage via a lubricated, atraumatically placed catheter immediately before BCG instillation under gravity. Additional rolling and posi tional manoeuvers by the patient after instillation are unnecessary for complete contact with the urothelium and distribution of BCG. Local symptoms of bladder irri tability are quite common with 60% of patients in clinical trials experiencing dysuria. 22, 35 Symptom management, such as use of singledose, shortterm quinolones 6 h after BCG instillation and/or use of anticholinergics, has been shown to decrease moderate to severe adverse events in some published reports, 36, 37 and enables the majority (90%) of patients to tolerate fulldose BCG without discontinuation of therapy. 38 
Definition of BCG failure
Recognizing when BCG has failed is another area that can lead to confusion. Although the assumption seems logical that any tumour recurrence after therapy is a 'BCG failure' , not all patients in this population have a similar prognosis. This situation has immense impli cations on options for alternative therapy, including the need to proceed to cystectomy. Definitions to clarify what constitutes BCG failure have been published. 39 Herr & Dalbagni 40 The above definitions highlight a major problem with the design of current clinical trials for bladder cancer using intravesical BCG therapy: lack of a stand ard definition of treatment failure and the complexity and ambiguity associated with related terminology. The situation becomes even more complex when the adequacy of BCG therapy is considered, as induction BCG alone is considered suboptimal therapy. Thus, when designing clinical trials for intravesical therapy, most clinicians recognize that to be included in a BGC failure trial patients should receive at least five of six doses of induction BCG and at least two of three doses of maintenance BCG. This requirement brings about its own challenge: the lack of a good control group (other than cystectomy) for true BCG failures. If patients have recurrent highgrade tumours after BCG therapy as listed above, the salvage rates with intravesical therapy remain low. Thus, no clinical trial that randomizes BCGrefractory patients to alternative conservative measures compared to the much more invasive treat ment of radical cystectomy has been proposed or even felt to be feasible to date.
Improving enrolment in clinical trials of new intra vesical therapies will require changes in study design and approach. One such proposal is based on early identifi cation of patients who experience 'cytogenetic failure' of BCG therapy. This suggestion is based on a prospective clinical trial, in which fluorescence in situ hybridization (FISH) assays that detect aneuploidy and gene muta tion in urine samples (UroVysion, Abbott Molecular) were performed serially during BCG therapy. The data suggested that patients with a positive result in the FISH assay and a negative 3month cystoscopy are at such high risk of recurrence and progression that their disease can be classified as a cytogenetic BCG failure, even though they are clinically diseasefree. 43 Thus, a proposed clinical trial design might include randomiz ing such patients to further BCG (as is standard of care) or alternative therapy that has previously demonstrated robust activity in other phase II trials. 44 
Predictors of response to BCG
Markers of response to intravesical BCG fall into three broad categories: determination of response (presence of cancer), use of surrogate endpoint biomarkers and prediction of response. BCG is most frequently used to treat highgrade disease and assessing the response of CIS specifically is challenging because it is often diffi cult to detect. A commonly used design is to determine response by cystoscopy, cytology and possibly bladder biopsy at 3 months and 6 months following a BCG induction regimen. However, the 3month assessment is problematic because of the well documented conver sion of positive cytology at 3 months to negative cyto logy at 6 months, particularly after maintenance BCG. 12 Fluorescence cystoscopy can improve detection of both CIS and papillary bladder cancer, but fluorescence can also be induced by inflammation. 45 It remains to be seen whether fluorescence cystoscopy can reliably improve the determination of BCG response.
Cytology is a subjective test with variable perfor mance; 46 molecular tests that are more objective might yield better and more consistent performance in detect ing visually occult bladder cancer. Patients who have abnormal results in the UroVysion assay in a urine sample obtained immediately before the last of the 6week induction instillations have increased risk for tumour recurrence and progression. 43 Cytokine production has been explored as a source of potential surrogate endpoint biomarkers. Increased levels of IL8 within 6 h and increased levels of IL18 within 12 h of the first BCG dose correlate with response to BCG treatment. 47 Detection of IL2 in the patient's urine during induction and the first mainten ance treat ment is associated with a favourable response to BCG. 48 Similarly, patients receiving BCG whose peripheral blood mononuclear cells produce IL2 in response to challenge with phytohaemagglutinin are likely to have a favourable response to BCG. 49 A team from the MD Anderson Cancer Center has developed a nomo gram based on the measurement of multiple cytokines that predicts response with an area under a receiver o perating characteristics curve value of 0.85.
50
Response to immunotherapy with BCG depends on complex molecular interactions between the patient and their cancer. Genomic variations in oxidative stress pathway genes might affect response to BCG. 51 Similarly, polymorphisms in immune response genes in combi nation with clinicopathological features can be used to distinguish patient groups with varying risk of relapse free survival after BCG treatment. 52 This approach is supported by evidence of a specific gene signature that is associated with response to BCG. 53 Molecular analy sis has defined clinically relevant subtypes of bladder 
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cancer. 54 These tumours differ in their response to chemotherapy, but it is not yet clear if these molecu lar phenotypes significantly differ in their response to BCG. Increasing knowledge of the multiple factors that influence what is clinically recognized as a BCG response is likely to result in improved instruments to assess this response.
Options after BCG failure
BCG treatment eventually fails in up to 50% of patients and in about half of those within the first 6 months. 55 In tumours that do not respond to BCG anymore, conventional intravesical chemotherapy agents, such as doxorubicin, thiotepa and mitomycin, have limited activity. In addition, valrubicin, the only FDAapproved drug for BCGrefractory CIS, is only effective in <10% of patients at 2 years and none with coincident stage T1 disease. 56 Thus, the traditional approach after BCG treatment failure has been to advocate early cystec tomy. 57 However, several lines of evidence suggest a reasonably safe window of opportunity, probably up to 1.5-2 years after onset of the index highgrade tumour, in which other conservative, nonradical therapies might be tried without undue risk. [58] [59] [60] [61] Repeated BCG induction is of limited value. About onethird of patients who do not respond to one course of BCG will eventually achieve a durable response. However, after further courses, the typical success rate of repeated BCG is <1020%. 41, 62, 63 After recognizing that BCG exerts its effects via cytokine stimulation, as well as response of type 1 T helper cells (T H 1) and T helper cell recruitment, the addi tion of cytokine therapy to BCG treatment has been tried. For example, IFNα2b functions by enhancing protein TRAIL release, augmenting the T H 1 response, increasing IFNγ release and reducing the expression of inflammationinhibiting proteins such as IL10. 64, 65 Although intravesical IFNα provides a 2year disease free rate of only 12% for BCGrefractory CIS, 66 several phase I and phase II studies indicate a robust response of around 50% for the combination of BCG with IFNα2b in patients who have not responded to BCG alone. However, not all patients have the optimum salvage response that is observed in those who initially responded to BCG and developed recurrent tumours in a delayed fashion (>1 years later). [67] [68] [69] [70] Longterm studies of up to 5 years show that, although early responses to the BCG-interferon treatment were excellent, 64% of patients had relapsed at 5 years with 20% having evidence of disease progression. 71 The combination of reduceddose BCG with IFNα has shown favourable longterm results in firsttime BCG failures. 70, 72 By con trast, the only randomized study of the combination of BCG with IFNα2b in BCGnaive patients failed to demonstrate any superiority of the combination over BCG alone, even though the tolerability of reduced dose BCG-IFNα2b seemed to be better than that of fulldose BCG alone. 73 Nevertheless, the lack of RCTs and lack of superiority of BCG-IFN versus BCG alone in BCGnaive patients has limited the widespread use of this combination treatment. Furthermore, even this therapy has unsatisfactory activity in BCGrefractory patients. The combination of BCG with IL12, which is known to promote T H 1 response and interferon release, has been studied in mice. Intravesical admin istration of a combination of BCG and IL12 resulted in higher urine and serum levels of IFNγ, especially after the third instillation, in comparison to either agent alone. 74 Longterm outcome data for this treatment c ombination are not available.
Other alternative strategies have been developed for patients who experience a failure of BCG therapy. For example, the use of initial chemotherapy followed by BCG, the reverse version or alternating application, as well as other novel chemotherapy regimens, have been investigated in small clinical studies. 55 In addition, several original approaches using electromotive accelera tion have been investigated. Kaasinen et al. 75 conducted a study in 236 patients with recurrent Ta or T1 bladder tumours. Eligible patients received five weekly instilla tions of mitomycin C and were subsequently randomized to monthly BCG only or alternating BCG and IFNα2b. They found a significantly lower recurrence rate in the arm treated with mitomycin C followed by BCG only, indicating no benefit of IFNα2b in this situation. The use of hyperthermic conditions with intravesical mito mycin C can increase the response rate compared with euthermic conditions. Hyperthermic conditions resulted in a significant improvement in longterm diseasefree survival. 76 In another combination approach, Di Stasi et al. 77 administered electromotive mitomycin C alter nating with BCG compared with BCG alone in a com plicated schedule that also included maintenance therapy in the complete responders. In this randomized trial, patients receiving the combination therapy demon strated a significantly lower recurrence rate (42% versus 58%, P = 0.0012). The randomized EORTC30993 trial compared sequential mitomycin C and BCG to BCG alone, but did not demonstrate any benefit of the combi nation treatment in terms of recurrence or progression. 78 Results from an aggregate metaanalysis did not show any difference in response rates or progression between administering chemotherapy and BCG concomitantly or in sequence. 79 However, the combination approach did trend towards reduced recurrence (relative risk 0.75) and progression (relative risk 0.45) for patients with Ta or T1 tumours, while not having much benefit in those with CIS.
Several approved chemotherapeutics that are active in advanced disease, including cisplatin, gemcitabine and taxanes, are being studied for intravesical use. Unfortunately, the most active single systemic agent, cis platin, is associated with unpredictable and sometimes fatal anaphylaxis when used intravesically. 80 By contrast, intravesical gemcitabine is particularly active in patients with intermediate risk papillary disease in whom BCG treatment has failed, even demonstrating superiority in comparison with mitomycin. 81, 82 However, two studies of gemcitabine in BCGrefractory disease resulted in 2year durable responses of only 7% and 21%.
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Intravesical docetaxel has shown good activity, even in BCGrefractory NMIBC. Among 54 patients, 59% experi enced a complete response, 40% were disease free at 12 months, and 25% at 3 years. Cystectomy was required in 24% with an overall 5year diseasespecific survival of 85%. 85 Intravesical multiagent chemotherapy in NMIBC has only recently been investigated. Past combinations of harsher, vesicant drugs, such as doxorubicin and mito mycin, although highly active, resulted in considerable local chemical cystitis. 86 By contrast, newer nonvesicant drugs, such as gemcitabine and docetaxel, are very well tolerated. 87, 88 Sequential gemcitabine-mitomycin C in 47 patients with highrisk disease, primarily after BCG failure, resulted in a complete response in 68% of patients with 1year and 2year diseasefree survival of 48% and 38%, respectively. 89 Alternatively, sequenced g emcitabine-docetaxel in 45 patients with highrisk disease yielded a complete response rate of 66%, as well as 1year and 2year recurrencefree survival of 54% and 34%, respectively. 90 Reassuringly, although the cystec tomy rate for both regimens was around 20%, metastasis was rarely reported.
Radiation as an option for recurrent disease
Cystectomy remains the standard for recurrent BCG refractory, highgrade T1 bladder tumours. However, many patients (especially the elderly) are not under going surgery, possibly owing to comorbidities and/ or a desire to avoid a large operation. 91 Furthermore, the high rates of clinicopathological stage discordance noted after surgery (around 45% of T1 tumours are being upstaged) might contribute to the poor long term results of secondline intravesical agents f ollowing BCG failure. 92 Radiation therapy presents a nonsurgical option for BCG failures. Early studies showed reasonable response rates (48-69%), 93, 94 and one randomized trial in patients with highgrade T1 tumours comparing conservative treatment with radiation alone showed no difference between treatments in terms of recurrence. 95 There is increasing data on combined radiochemo therapy for highrisk NMIBC following maximum trans urethral resection of the bladder tumour (TURBT). One study compared radiotherapy or radiochemo therapy in 141 patients and reported a complete response rate of 88%; at 5 years and 10 years, overall progression rates were 19% and 30% (13% and 29% for highgrade T1 tumours) and overall diseasespecific survival was 82% and 73% (89% and 79% for complete responders, 80% and 71% for highgrade T1 tumours), respectively. 96 Over 80% of survivors could retain their native bladder and around 70% were "delighted" or "pleased" with their urinary function. A second study reported on 17 patients undergoing trimodality therapy (TURBT, radiation and chemotherapy) following T2 recurrence after failure of BCG for noninvasive disease. 97 With 7 years followup time, only one patient required cystectomy, 10 patients (59%) were free of any bladder tumour recurrence and diseasespecific survival was 70%.
Based on current evidence, the new 2015 NCCN bladder cancer guideline states that externalbeam radiotherapy is rarely appropriate for patients with stage Ta, T1, or Tis disease. Radiochemotherapy might be a potentially curative alternative to cystectomy in patients with recurrent Ta-T1 disease (usually following BCG therapy but without extensive Tis). 98 Currently, the North American multicentre, cooperative Radiation Therapy Oncology Group (RTOG) protocol RTOG 0926 is evalu ating the role of radiochemotherapy (61.2 Gy with con current cisplatin or 5fluorouracil plus mito mycin C) after maximum TURBT for patients with highrisk T1 bladder cancer following BCG failure for whom the next therapy would have been radical cystectomy. 99 
Novel agents
Currently, several strategies to enhance BCG response are being explored. Testing of combinations of BCG with various new investigational agents that have inde pendently demonstrated activity in early phase trials is ongoing and some of these combinations have been applied clinically with variable effect. In addition, the use of entirely novel agents based on emerging preclini cal findings presents an important area for potential clinical investigation.
Some bladder cancer cells have a high level of VEGF expression. Tyrosine kinase inhibitors, such as suni tinib, can inhibit proliferation of such cells. In vitro experiments using T24 bladder cancer cells have dem onstrated that the combination of sunitinib and BCG can enhance cell death and reduce cell migration compared with sequential administration. 100 It remains to be seen whether similar responses can be obtained in vivo or in humans. Smac mimetics degrade inhibitors of apop tosis (IAP) proteins, which can block caspaseinduced apoptotic death, and have been studied for augmenting response to BCG. 101 One of the mechanisms of action of BCG is to enhance release of protein TRAIL from neutro phils, which can be inhibited by IAP proteins. 102, 103 In one in vitro study, application of BCGconditioned neutrophil medium along with a small molecule Smac mimetic resulted in enhanced cytotoxicity compared with the use of BCG alone. 104 Finally, trapping of BCG by exogenously introduced fibrinogen can enhance local concentration of BCG and uptake via fibronectin. This strategy has been shown to enhance BCG response in vitro. 105 Other developments in oncology might also affect the future of intravesical treatment in bladder cancer. The immune checkpoint inhibitors ipilimumab and pem brolizumab (antibodies that target CTLA4 and PD1, respectively) have been approved for use in advanced melanoma. The receptor PD1 is one checkpoint of Tcell function and is activated by PDL1 and PDL2. AntiCTLA4 and antiPD1 antibodies can prolong and enhance the Tcell response. In bladder tumours, PDL1 expression has been correlated with bladder cancer Tstage and is highest in T3/T4 and CIS. 106 In addition, immunohistochemical data suggest that PDL1 expression is increased in tumours from patients with BCG failure.
106 PDL1 and PDL2 can also be inhib ited and could provide an alternative strategy, as some evidence exists that inhibition of PDL1 might avoid autoimmune responses, which are usually modulated by PDL2. IDO1 inhibitors can work in a fashion similar to PD1 inhibitors to enhance T H activity. One such inhibitor, indoximod is currently being studied in a clinical trial for advanced prostate cancer and could potentially be used together with BCG to enhance response. 107 Currently, immune checkpoint inhibitors for the treatment of bladder cancer are being evaluated in the advanced disease setting, but they might also have a role in earlystage disease in combination with BCG.
Intravesical therapy with a conditionally replicating adenovirus that was genetically engineered to express GMCSF was well tolerated and induced a local immune response. 108 Instillation of a nonreplicating adenoviral vector encoding IFNα2b together with the exipient Syn3 to enhance gene transfer also seemed to be well toler ated and could yield responses. 109 Photodynamic therapy is another novel approach to bladder cancer therapy. Several early studies suggested a benefit and one small study in 34 patients reported a favourable diseasefree recurrence rate. [110] [111] [112] However, despite the novelty in these and other approaches, none have been evaluated in a definitive, practicechanging study or are currently considered standard therapy.
Another treatment for NMIBC are toxic protein con jugates. These agents contain both a targeting and a treatment component to increase specificity for cancer cells. One clinical example of this approach is denileu kin diftitox, a fusion of the diphtheria toxin and IL2, which targets a membrane receptor that is differen tially expressed in target cancer cells compared with the normal cells. 113 In bladder cancer, oportuzumab monatox, a recombinant fusion protein of an anti EpCAM antibody with the pseudomonas exotoxin, has been evaluated. In a phase II study in 46 BCGrefractory patients with CIS, 44% achieved a complete response with this therapy. 114 Other preclinical evaluations of this approach include targeting diphtheria toxin to the epidermal growth factor receptor (EGFR), which is frequently overexpressed in bladder cancer but not the normal urothelium. 115 Diphtheria toxin linked to EGF has shown encouraging results in murine orthotopic models of bladder cancer without any clear systemic or urothelial toxicity. 116 Nanotechnology can be directed to specific cells and then heated for focal thermal ablation with the application of external light energy. In bladder cancer therapy, direct intravesical delivery can avoid problems caused by systemic clearance. Gold nanorods conjugated to antiEGFR antibodies have been tested in bladder cancer cell lines using nearinfrared light. 117 A similar approach has been developed using gold nanorods target ing the fibroblast growth factor receptor, high lighting the generalizability of this approach based on the e xpression of target molecules on tumour cells. 118 One approach to address the toxicity observed with BCG treatment is the use of nonliveBCG immuno therapy. For example, BCG cell wall components have been incorporated into octaargininemodified lipo somes, which have similarities to an envelopetype virus, for cellular delivery. 119 In fact, a similar strategy was used in the MCNA agent, in which mycobacterial cell wall is complexed to nuclear DNA with the aim of achiev ing both immunological and direct cytotoxic effects. A recent study in 129 patients with highrisk disease after BCG failure suggested a high activity of this agent. 120 Overall diseasefree rate was 25.0% at 1 year and 19.0% at 2 years. In patients with papillaryonly tumours, MCNA was even more effective with rates of 35.1% and 32.2% at 1 year and 2 years, respectively.
Conclusion
Immunotherapy for patients with NMIBC remains the gold standard, with efficacy of intravesical BCG surpass ing that of chemotherapy. In order for BCG immuno therapy to be effective, however, practitioners must learn (or relearn) how to use it in an optimal manner. First, patient selection is paramount and complete resection of all visible tumours is important, not only for staging, but also to improve outcomes. BCG induction with 6week instillations must be followed by 3week main tenance instillations, as recommended in the SWOG protocol, as no other maintenance schedule has been shown to work reliably. If a patient develops recurrence on BCG therapy, the timing and tumour characteristics of this recurrence should be considered when classify ing the patient in the subgroups within the BCGfailure category. Although radical cystectomy remains the main stay for patients with highrisk BCG failure, for those who are unfit or who refuse cystectomy, several alter native options exist as outlined in this Expert Consensus Document. Future strategies aimed at improving the immune response of patients (with or without BCG), deviceassisted chemo therapy delivery and c ombination chemotherapy all seem to be promising alternatives.
